Fluzoparide combined with apatinib mesylate in the treatment of platinum resistant recurrent ovarian cancer: A single arm, single center, prospective clinical study

被引：0
|
作者：
Sun, L. X. [1 ]
Zhao, H. W. [1 ]
机构：
[1] Shanxi Canc Hosp, Dept Med, Taiyuan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
823TiP
引用
收藏
页码：S772 / S772
页数：1
相关论文
共 50 条
  • [31] A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibitor
    Wang, J.
    Shen, Y.
    Chen, J.
    Chen, X.
    Guan, Q.
    Liu, Q.
    Xu, J.
    Xu, Y.
    Zhang, B.
    Zhang, H.
    Zhu, Y.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1513 - S1513
  • [32] A Phase II, Single-Arm, Prospective Clinical Trial for the Efficacy and Safety of Apatinib Combined With Capecitabine in Therapy for Recurrent/Metastatic and Persistent Cervical Cancer After Radiochemotherapy
    Li, J.
    Mao, W.
    Li, F.
    Ran, L.
    Chang, J.
    Mei, F.
    Hu, L.
    Du, Y.
    Tian, X.
    Liu, M.
    Chen, Y.
    Shan, L.
    Mu, J.
    Yin, S.
    Qin, Y.
    Liang, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E616 - E617
  • [33] A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
    Yang, Mi
    Liu, Xiufeng
    Zhang, Cheng
    Liao, Feng
    Li, Zixiong
    Luo, Xianwen
    Sun, Yiran
    Chen, Chao
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 8869 - 8876
  • [34] PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
    Baghmar, S.
    Agarwal, A.
    Gauda, C.
    Qureshi, S.
    Malik, P. S.
    Vaibhav, V.
    ANNALS OF ONCOLOGY, 2019, 30
  • [35] Anlotinib combined with niraparib dual therapy in platinum-resistant recurrent ovarian clear cell carcinoma (CC-ANNIE): A single-center, single-arm, phase 2 trial
    Zhang, Bingzhong
    Lin, Shaodan
    Peng, Yongpai
    Xu, Guocai
    Li, Jing
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S284 - S285
  • [36] Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
    Zhongmian Pan
    Zhongbin Luo
    Hongying He
    Yujie Chen
    Bingbing Zhao
    Zhijun Yang
    Li Li
    Journal of Ovarian Research, 16
  • [37] Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
    Pan, Zhongmian
    Luo, Zhongbin
    He, Hongying
    Chen, Yujie
    Zhao, Bingbing
    Yang, Zhijun
    Li, Li
    JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)
  • [38] Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases
    Cheng, Yuan
    Zhang, Juan
    Geng, Haiyun
    Qin, Shukui
    Hua, Haiqing
    ONCOTARGETS AND THERAPY, 2018, 11 : 1989 - 1995
  • [39] Comparison of Weekly Paclitaxel Regimens in Recurrent Platinum-Resistant Ovarian Cancer: A Single Institution Retrospective Study
    Morin, Laurence
    Grenier, Louis-Philippe
    Foucault, Nicolas
    Levesque, Eric
    Fabi, Francois
    Langlais, Eve-Lyne
    Sebastianelli, Alexandra
    Lavoie, Marianne
    Lalancette, Marc
    Plante, Marie
    Singbo, Mahukpe Narcisse Ulrich
    Castonguay, Vincent
    CURRENT ONCOLOGY, 2024, 31 (08) : 4624 - 4631
  • [40] Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study
    Dragomir, Radu
    Sas, Ioan
    Saftescu, Sorin
    Popovici, Dorel
    Margan, Roxana
    Dragomir, Adelina Silvana
    Stanca, Horia
    Mocanu, Valeria
    Pac, Cristina
    Negru, Serban
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)
12345